Our study provides a novel, yet unexpected, finding: loss of ASIC2 and βENaC leads to remarkable protection against HFD-induced weight gain, intrabdominal fat accumulation, hepatic steatosis, insulin resistance, and plasma lipid profile changes. The gene discussed is ASIC2; the disease is Hepatic steatosis.